CL2015003470A1 - Moduladores del receptor cxcr7. - Google Patents

Moduladores del receptor cxcr7.

Info

Publication number
CL2015003470A1
CL2015003470A1 CL2015003470A CL2015003470A CL2015003470A1 CL 2015003470 A1 CL2015003470 A1 CL 2015003470A1 CL 2015003470 A CL2015003470 A CL 2015003470A CL 2015003470 A CL2015003470 A CL 2015003470A CL 2015003470 A1 CL2015003470 A1 CL 2015003470A1
Authority
CL
Chile
Prior art keywords
cxcr7
receiver modulators
modulators
receiver
heterociclic
Prior art date
Application number
CL2015003470A
Other languages
English (en)
Spanish (es)
Inventor
Heinz Fretz
Thierry Kimmerlin
Philippe Guerry
Francois Lehembre
Julien Pothier
Hervé Siendt
Anja Valdenaire
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CL2015003470A1 publication Critical patent/CL2015003470A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
CL2015003470A 2013-05-30 2015-11-27 Moduladores del receptor cxcr7. CL2015003470A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2013054478 2013-05-30

Publications (1)

Publication Number Publication Date
CL2015003470A1 true CL2015003470A1 (es) 2016-06-17

Family

ID=50943357

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003470A CL2015003470A1 (es) 2013-05-30 2015-11-27 Moduladores del receptor cxcr7.

Country Status (30)

Country Link
US (1) US9920010B2 (cg-RX-API-DMAC10.html)
EP (1) EP3004082B1 (cg-RX-API-DMAC10.html)
JP (1) JP6393749B2 (cg-RX-API-DMAC10.html)
KR (1) KR102302580B1 (cg-RX-API-DMAC10.html)
CN (1) CN105263924B (cg-RX-API-DMAC10.html)
AR (1) AR096490A1 (cg-RX-API-DMAC10.html)
AU (1) AU2014272718B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015030095B1 (cg-RX-API-DMAC10.html)
CA (1) CA2912133C (cg-RX-API-DMAC10.html)
CL (1) CL2015003470A1 (cg-RX-API-DMAC10.html)
CY (1) CY1119537T1 (cg-RX-API-DMAC10.html)
DK (1) DK3004082T3 (cg-RX-API-DMAC10.html)
EA (1) EA028604B1 (cg-RX-API-DMAC10.html)
ES (1) ES2645470T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20171597T1 (cg-RX-API-DMAC10.html)
HU (1) HUE036649T2 (cg-RX-API-DMAC10.html)
IL (1) IL242782B (cg-RX-API-DMAC10.html)
LT (1) LT3004082T (cg-RX-API-DMAC10.html)
MA (1) MA38679B1 (cg-RX-API-DMAC10.html)
MX (1) MX364104B (cg-RX-API-DMAC10.html)
MY (1) MY173564A (cg-RX-API-DMAC10.html)
NO (1) NO3004082T3 (cg-RX-API-DMAC10.html)
PH (1) PH12015502632B1 (cg-RX-API-DMAC10.html)
PL (1) PL3004082T3 (cg-RX-API-DMAC10.html)
PT (1) PT3004082T (cg-RX-API-DMAC10.html)
SG (1) SG11201509057UA (cg-RX-API-DMAC10.html)
SI (1) SI3004082T1 (cg-RX-API-DMAC10.html)
TW (1) TWI640510B (cg-RX-API-DMAC10.html)
UA (1) UA118562C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014191929A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
US10202368B2 (en) 2014-12-01 2019-02-12 Idorsia Pharmaceuticals Ltd. CXCR7 receptor modulators
US20170112831A1 (en) * 2015-10-23 2017-04-27 James MERRITT Use of ccr1 antagonists as a treatment for tumors of the central nervous system
EP3490986B1 (en) * 2016-07-28 2021-11-24 Idorsia Pharmaceuticals Ltd Piperidine cxcr7 receptor modulators
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
KR102502046B1 (ko) 2018-01-26 2023-02-20 이도르시아 파마슈티컬스 리미티드 Cxcr7 수용체 작동제 (3s,4s)-1-시클로프로필메틸-4-{[5-(2,4-디플루오로-페닐)-이속사졸-3-카르보닐]-아미노}-피페리딘-3-카르복실산 (1-피리미딘-2-일-시클로프로필)-아미드의 결정질 형태

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896170A (en) 1969-02-26 1975-07-22 American Home Prod Intermediates for the preparation of 1,3-dihydro-2h-1, -benzodiazepin-2-ones
RU2214405C2 (ru) 1998-02-18 2003-10-20 НьюроСёрч А/С Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов
GB9816984D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US7256201B2 (en) 2000-12-07 2007-08-14 Astrazeneca Ab Selective estrogen receptor-β ligands
ATE427933T1 (de) 2002-12-20 2009-04-15 Chemocentryx Inc Inhibitoren der bindungder chemokine i-tac bzw. sdf-1 an den ccxckr2-rezeptor
ATE486875T1 (de) * 2005-11-10 2010-11-15 Chemocentryx Inc Substituierte chinolone und verwendungsverfahren
US20100331298A1 (en) 2007-12-10 2010-12-30 Cytopathfinder, Inc. Carboxamide Compounds and Their Use
AR091516A1 (es) * 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
US10202368B2 (en) 2014-12-01 2019-02-12 Idorsia Pharmaceuticals Ltd. CXCR7 receptor modulators

Also Published As

Publication number Publication date
PH12015502632A1 (en) 2016-03-07
MY173564A (en) 2020-02-04
LT3004082T (lt) 2017-10-25
EA028604B1 (ru) 2017-12-29
MA38679B1 (fr) 2019-12-31
PT3004082T (pt) 2017-11-13
HUE036649T2 (hu) 2018-07-30
SG11201509057UA (en) 2015-12-30
US9920010B2 (en) 2018-03-20
KR20160013197A (ko) 2016-02-03
AU2014272718B2 (en) 2018-06-28
BR112015030095B1 (pt) 2023-02-28
JP6393749B2 (ja) 2018-09-19
AU2014272718A1 (en) 2016-01-21
DK3004082T3 (en) 2017-10-02
WO2014191929A1 (en) 2014-12-04
CN105263924B (zh) 2018-10-19
EP3004082A1 (en) 2016-04-13
ES2645470T3 (es) 2017-12-05
EA201501163A1 (ru) 2016-06-30
CY1119537T1 (el) 2018-03-07
IL242782A0 (en) 2016-02-01
PL3004082T3 (pl) 2018-01-31
CA2912133C (en) 2021-06-22
US20160107997A1 (en) 2016-04-21
NZ715530A (en) 2020-12-18
HK1223353A1 (en) 2017-07-28
NO3004082T3 (cg-RX-API-DMAC10.html) 2017-12-30
TW201529557A (zh) 2015-08-01
EP3004082B1 (en) 2017-08-02
UA118562C2 (uk) 2019-02-11
MA38679A1 (fr) 2018-07-31
AR096490A1 (es) 2016-01-13
MX2015016429A (es) 2016-03-01
BR112015030095A2 (pt) 2022-07-12
IL242782B (en) 2019-06-30
MX364104B (es) 2019-04-12
KR102302580B1 (ko) 2021-09-15
HRP20171597T1 (hr) 2017-12-01
SI3004082T1 (sl) 2017-11-30
CN105263924A (zh) 2016-01-20
JP2016520120A (ja) 2016-07-11
PH12015502632B1 (en) 2016-03-07
TWI640510B (zh) 2018-11-11
CA2912133A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CL2016001871A1 (es) Anticuerpos humanos para pd-1
ECSP17044494A (es) Receptores de antígenos quiméricos de bcma
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
ECSP17023281A (es) Inhibidores de mk2 y sus usos
MX2020007166A (es) Composiciones para modular la expresion de sod-1.
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
EA201691582A1 (ru) Новые фармацевтические препараты
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
CL2016002936A1 (es) Bisagra de fricción para computadoras de tipo tableta
CL2015002121A1 (es) Modulares de receptores nmda de espiro-lactama y sus usos.
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
CU20170018A7 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
CL2016002084A1 (es) Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina.
MX388752B (es) Composiciones novedosas, usos y métodos para hacerlas.
MX389256B (es) Compuestos heterociclicos y usos de los mismos.
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
IL252089A0 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
UY34616A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
MX2016012219A (es) Agonistas de receptor fgf21 y usos del mismo.
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf